Company Profile

23andMe Stock Price, News & Analysis

Ticker:
ME
Exchange:
NASDAQ
Sector:
Biotechnology
Location:
United States

Stock performance

0.61 USD

Close

Last updated: March 28, 2025 at 00:00

Market cap

Why the stock is moving

ME is trading with a steady catalyst profile while investors wait for the next headline that changes the story.

Company overview

Business overview

23andMe is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Geographic Base and Sector Classification

Headquartered in the United States and listed on NASDAQ, 23andMe is followed within the biotech universe for its exposure to catalyst-driven execution.

Business Model Characteristics

23andMe follows a catalyst-driven model where the market watches how the company turns development work into repeatable value creation.

Position Within the Biotechnology Landscape

Compared with more mature healthcare peers, 23andMe sits closer to the development side of the biotechnology landscape, where timing around data and approvals matters most.

Future catalysts

Recent news

The five most recent related feed items are shown below in reverse chronological order.

  1. 01

    Zimmer Biomet Names Chintan Desai President of Asia Pacific Region

    ZBH · Source: Zimmer Biomet

  2. 02
  3. 03
  4. 04
  5. 05

Similar stocks

Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.

Frequently Asked Questions

What is the current stock price of 23andMe (ME)?

23andMe (ME) most recently closed at 0.61 USD.

What does 23andMe do?

23andMe is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

On which exchange is ME stock listed?

23andMe (ME) is associated with NASDAQ, United States, Biotechnology.

What is Investors?

Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Which conditions is 23andMe targeting with Investors?

23andMe is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.